These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 35073333)

  • 41. Skin cancer (Basal cell carcinoma, squamous cell carcinoma, and malignant melanoma): new cases, treatment practice, and health care costs in new brunswick, Canada, 2002-2010.
    Pilgrim W; Hayes R; Hanson DW; Zhang B; Boudreau B; Leonfellner S
    J Cutan Med Surg; 2014 Oct; 18(5):320-31. PubMed ID: 25186993
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Age of BLood Evaluation (ABLE) randomised controlled trial: description of the UK-funded arm of the international trial, the UK cost-utility analysis and secondary analyses exploring factors associated with health-related quality of life and health-care costs during the 12-month follow-up.
    Walsh TS; Stanworth S; Boyd J; Hope D; Hemmatapour S; Burrows H; Campbell H; Pizzo E; Swart N; Morris S
    Health Technol Assess; 2017 Oct; 21(62):1-118. PubMed ID: 29067906
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Survey among patients with basal cell carcinoma in The Netherlands.
    Gerritsen MJ; De Rie MA; Beljaards RC; Thissen MR; Kuipers MV
    J Dermatolog Treat; 2009; 20(4):213-8. PubMed ID: 19125362
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost comparisons of managing complex facial basal cell carcinoma: Canadian study.
    Lear W; Mittmann N; Barnes E; Breen D; Murray C
    J Cutan Med Surg; 2008; 12(2):82-7. PubMed ID: 18346405
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Supported self-management for patients with moderate to severe chronic obstructive pulmonary disease (COPD): an evidence synthesis and economic analysis.
    Jordan RE; Majothi S; Heneghan NR; Blissett DB; Riley RD; Sitch AJ; Price MJ; Bates EJ; Turner AM; Bayliss S; Moore D; Singh S; Adab P; Fitzmaurice DA; Jowett S; Jolly K
    Health Technol Assess; 2015 May; 19(36):1-516. PubMed ID: 25980984
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment of basal cell carcinomas by general practitioners in Australia.
    Streeton CL; Gospodarevskaya E; Harris A
    Int J Dermatol; 2006 Apr; 45(4):345-51. PubMed ID: 16650155
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cost-effectiveness of nurse-led multifactorial care to prevent or postpone new disabilities in community-living older people: Results of a cluster randomized trial.
    Suijker JJ; MacNeil-Vroomen JL; van Rijn M; Buurman BM; de Rooij SE; Moll van Charante EP; Bosmans JE
    PLoS One; 2017; 12(4):e0175272. PubMed ID: 28414806
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cost Effectiveness of the Angiotensin Receptor Neprilysin Inhibitor Sacubitril/Valsartan for Patients with Chronic Heart Failure and Reduced Ejection Fraction in the Netherlands: A Country Adaptation Analysis Under the Former and Current Dutch Pharmacoeconomic Guidelines.
    Ramos IC; Versteegh MM; de Boer RA; Koenders JMA; Linssen GCM; Meeder JG; Rutten-van Mölken MPMH
    Value Health; 2017 Dec; 20(10):1260-1269. PubMed ID: 29241885
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A randomised controlled trial of the clinical effectiveness and cost-effectiveness of the levonorgestrel-releasing intrauterine system in primary care against standard treatment for menorrhagia: the ECLIPSE trial.
    Gupta JK; Daniels JP; Middleton LJ; Pattison HM; Prileszky G; Roberts TE; Sanghera S; Barton P; Gray R; Kai J;
    Health Technol Assess; 2015 Oct; 19(88):i-xxv, 1-118. PubMed ID: 26507206
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The cost-utility of stepped-care algorithms according to depression guideline recommendations - Results of a state-transition model analysis.
    Meeuwissen JAC; Feenstra TL; Smit F; Blankers M; Spijker J; Bockting CLH; van Balkom AJLM; Buskens E
    J Affect Disord; 2019 Jan; 242():244-254. PubMed ID: 30216769
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Differences in health care resource utilization and costs for keratinocyte carcinoma among racioethnic groups: A population-based study.
    Sierro TJ; Blumenthal LY; Hekmatjah J; Chat VS; Kassardjian AA; Read C; Armstrong AW
    J Am Acad Dermatol; 2022 Feb; 86(2):373-378. PubMed ID: 34246700
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A systematic review of the clinical effectiveness and cost-effectiveness and economic modelling of minimal incision total hip replacement approaches in the management of arthritic disease of the hip.
    de Verteuil R; Imamura M; Zhu S; Glazener C; Fraser C; Munro N; Hutchison J; Grant A; Coyle D; Coyle K; Vale L
    Health Technol Assess; 2008 Jun; 12(26):iii-iv, ix-223. PubMed ID: 18513467
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cost-Utility of Stepped Care Targeting Psychological Distress in Patients With Head and Neck or Lung Cancer.
    Jansen F; Krebber AM; Coupé VM; Cuijpers P; de Bree R; Becker-Commissaris A; Smit EF; van Straten A; Eeckhout GM; Beekman AT; Leemans CR; Verdonck-de Leeuw IM
    J Clin Oncol; 2017 Jan; 35(3):314-324. PubMed ID: 27918712
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost-effectiveness of a pro-active approach of urinary incontinence in women.
    Vermeulen KM; Visser E; Messelink EJ; Schram AJ; Berger MY; de Bock GH; Dekker JH
    BJOG; 2016 Jun; 123(7):1213-20. PubMed ID: 26834046
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cumulative risks and rates of subsequent basal cell carcinomas in the Netherlands.
    Flohil SC; Koljenović S; de Haas ER; Overbeek LI; de Vries E; Nijsten T
    Br J Dermatol; 2011 Oct; 165(4):874-81. PubMed ID: 21711333
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cost-Effectiveness of Facilitated Access to a Self-Management Website, Compared to Usual Care, for Patients With Type 2 Diabetes (HeLP-Diabetes): Randomized Controlled Trial.
    Li J; Parrott S; Sweeting M; Farmer A; Ross J; Dack C; Pal K; Yardley L; Barnard M; Hudda M; Alkhaldi G; Murray E
    J Med Internet Res; 2018 Jun; 20(6):e201. PubMed ID: 29884608
    [TBL] [Abstract][Full Text] [Related]  

  • 58. VivaScope® 1500 and 3000 systems for detecting and monitoring skin lesions: a systematic review and economic evaluation.
    Edwards SJ; Mavranezouli I; Osei-Assibey G; Marceniuk G; Wakefield V; Karner C
    Health Technol Assess; 2016 Jul; 20(58):1-260. PubMed ID: 27483991
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Follow-up of basal cell carcinomas: an audit of current practice.
    Mc Loone NM; Tolland J; Walsh M; Dolan OM
    J Eur Acad Dermatol Venereol; 2006 Jul; 20(6):698-701. PubMed ID: 16836498
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Within trial cost-utility analysis of disease management program for patients hospitalized with atrial fibrillation: results from the SAFETY trial.
    Byrnes J; Ball J; Gao L; Kai Chan Y; Kularatna S; Stewart S; Scuffham PA
    J Med Econ; 2019 Sep; 22(9):945-952. PubMed ID: 31190590
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.